Report cover image

Lung Cancer Genomic Testing Market by Technology (Fluorescence In Situ Hybridization, Next-Generation Sequencing, Polymerase Chain Reaction), Sample Type (Liquid Biopsy, Tissue Biopsy), Panel Type, End User - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 181 Pages
SKU # IRE18445638

Description

Lung Cancer Genomic Testing Market by Technology (Fluorescence In Situ Hybridization, Next-Generation Sequencing, Polymerase Chain Reaction), Sample Type (Liquid Biopsy, Tissue Biopsy), Panel Type, End User - Global Forecast 2024-2030


The Lung Cancer Genomic Testing Market size was estimated at USD 1.01 billion in 2023 and expected to reach USD 1.07 billion in 2024, at a CAGR 8.00% to reach USD 1.73 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Lung Cancer Genomic Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Lung Cancer Genomic Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Lung Cancer Genomic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Admera Health, Agilent Technologies, Inc., BGI, CD Genomics, CeGaT GmbH, Centogene N.V., F. Hoffmann-La Roche AG, Illumina, Inc., Laboratory Corporation of America Holdings, NeoGenomics Laboratories, OncoDNA, OPKO Health, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc., and Veracyte, Inc..

Market Segmentation & Coverage

This research report categorizes the Lung Cancer Genomic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Technology

Fluorescence In Situ Hybridization

Next-Generation Sequencing

Polymerase Chain Reaction
Sample Type

Liquid Biopsy

Tissue Biopsy
Panel Type

Multi-Gene Panel

Single-Gene Panel
End User

Diagnostic Laboratories

Hospitals/Clinics

Research Organization
Region

Americas
Argentina
Brazil
Canada
Mexico
United States

California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas

Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam

Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Lung Cancer Genomic Testing Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Lung Cancer Genomic Testing Market?
3. What are the technology trends and regulatory frameworks in the Lung Cancer Genomic Testing Market?
4. What is the market share of the leading vendors in the Lung Cancer Genomic Testing Market?
5. Which modes and strategic moves are suitable for entering the Lung Cancer Genomic Testing Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

181 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Lung Cancer Genomic Testing Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising number of cancer incidences across the world
5.1.1.2. Government initiatives to expand access to lung cancer treatment
5.1.1.3. Growing number of research activities and collaborations to expand cancer care and prevention
5.1.2. Restraints
5.1.2.1. High cost of genetic testing services and the lack of reimbursement
5.1.3. Opportunities
5.1.3.1. Advancements in next-generation genome sequencing
5.1.3.2. Inclination toward adoption of personalized medicine and biomarker testing
5.1.4. Challenges
5.1.4.1. Stringent regulations concerning genetic and molecular testing
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Lung Cancer Genomic Testing Market, by Technology
6.1. Introduction
6.2. Fluorescence In Situ Hybridization
6.3. Next-Generation Sequencing
6.4. Polymerase Chain Reaction
7. Lung Cancer Genomic Testing Market, by Sample Type
7.1. Introduction
7.2. Liquid Biopsy
7.3. Tissue Biopsy
8. Lung Cancer Genomic Testing Market, by Panel Type
8.1. Introduction
8.2. Multi-Gene Panel
8.3. Single-Gene Panel
9. Lung Cancer Genomic Testing Market, by End User
9.1. Introduction
9.2. Diagnostic Laboratories
9.3. Hospitals/Clinics
9.4. Research Organization
10. Americas Lung Cancer Genomic Testing Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Lung Cancer Genomic Testing Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Lung Cancer Genomic Testing Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Abbott Laboratories
14.1.2. Admera Health
14.1.3. Agilent Technologies, Inc.
14.1.4. BGI
14.1.5. CD Genomics
14.1.6. CeGaT GmbH
14.1.7. Centogene N.V.
14.1.8. F. Hoffmann-La Roche AG
14.1.9. Illumina, Inc.
14.1.10. Laboratory Corporation of America Holdings
14.1.11. NeoGenomics Laboratories
14.1.12. OncoDNA
14.1.13. OPKO Health, Inc.
14.1.14. QIAGEN N.V.
14.1.15. Quest Diagnostics Incorporated
14.1.16. Thermo Fisher Scientific, Inc.
14.1.17. Veracyte, Inc.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
FIGURE 1. LUNG CANCER GENOMIC TESTING MARKET RESEARCH PROCESS
FIGURE 2. LUNG CANCER GENOMIC TESTING MARKET SIZE, 2023 VS 2030
FIGURE 3. LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. LUNG CANCER GENOMIC TESTING MARKET DYNAMICS
FIGURE 7. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 8. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2030 (%)
FIGURE 10. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2023 VS 2030 (%)
FIGURE 12. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 14. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. LUNG CANCER GENOMIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. LUNG CANCER GENOMIC TESTING MARKET SHARE, BY KEY PLAYER, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us